Accepted for Publication: July 30, 2012.
Published Online: September 24, 2012. doi:10.1001/2013.jamaneurol.79
Author Contributions:Study concept and design: Paterson, Haman, Miller, and Geschwind. Acquisition of data: Paterson, Torres-Chae, Kuo, Ando, Nguyen, Wong, Haman, Johnson, and Geschwind. Analysis and interpretation of data: Paterson, Torres-Chae, DeArmond, Garcia, Johnson, and Geschwind. Drafting of the manuscript: Paterson, Torres-Chae, Haman, and Geschwind. Critical revision of the manuscript for important intellectual content: Paterson, Torres-Chae, Kuo, Ando, Nguyen, Wong, DeArmond, Garcia, Johnson, Miller, and Geschwind. Statistical analysis: Paterson and Torres-Chae. Obtained funding: Geschwind. Administrative, technical, and material support: Torres-Chae, Kuo, Wong, Haman, Garcia, Johnson, and Geschwind. Study supervision: Kuo, Haman, Miller, and Geschwind.
Financial Disclosure: Dr Miller has been on scientific advisory boards for TauRx Ltd, Bristol-Myers Squibb, Siemens Molecular Imaging, and Sagol School of Neuroscience, Tel Aviv University and a steering committee for Allon Therapeutics and has received royalties from Cambridge University Press.
Funding/Support: This study was supported by National Institute on Aging grants K23AG021989, P01-AG021601, R01-AG031189, and P50-AG023501, National Institutes of Health National Institute of Neurological Disorders and Stroke contract N01-NS-0-2328, the Michael J. Homer Family Fund, National Institutes of Health National Center for Research Resources University of California, San Francisco Clinical and Translational Science Institute grant UL1 RR024131, and the John Douglas French Alzheimer's Foundation.
Additional Contributions: We thank the referring physicians; the National Prion Disease Pathology Surveillance Center for assistance with PRNP genetic analyses, prion typing, and pathological analyses; the Creutzfeldt-Jakob Disease Foundation for supporting our patients and families; and most importantly, our patients and their families.